Qiagen (NYSE:QGEN) Lifted to Hold at Kepler Capital Markets

Kepler Capital Markets upgraded shares of Qiagen (NYSE:QGEN) from a reduce rating to a hold rating in a research note issued to investors on Thursday morning, Briefing.com Automated Import reports.

A number of other research analysts have also weighed in on QGEN. Deutsche Bank lowered Qiagen from a buy rating to a hold rating in a report on Tuesday, October 8th. Piper Jaffray Companies dropped their target price on Qiagen from $36.00 to $31.00 and set a neutral rating on the stock in a report on Tuesday, October 8th. DZ Bank restated a neutral rating on shares of Qiagen in a report on Wednesday, July 24th. Zacks Investment Research upgraded Qiagen from a sell rating to a hold rating and set a $32.00 target price on the stock in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. upgraded Qiagen from an underweight rating to an overweight rating and raised their target price for the company from $25.00 to $40.00 in a report on Thursday. Ten equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $35.38.

Shares of QGEN stock traded up $3.28 during trading hours on Thursday, reaching $40.56. The company had a trading volume of 8,251,151 shares, compared to its average volume of 2,636,071. Qiagen has a 12 month low of $25.04 and a 12 month high of $41.55. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.45 and a quick ratio of 2.18. The business has a fifty day simple moving average of $30.26 and a 200-day simple moving average of $35.64. The company has a market cap of $8.41 billion, a price-to-earnings ratio of 30.27, a price-to-earnings-growth ratio of 2.78 and a beta of 0.83.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, October 30th. The company reported $0.36 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.01. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. The company had revenue of $382.70 million for the quarter, compared to analyst estimates of $382.98 million. During the same quarter last year, the company earned $0.35 earnings per share. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. On average, equities research analysts expect that Qiagen will post 1.4 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of QGEN. Private Capital Group LLC lifted its holdings in Qiagen by 354.0% during the second quarter. Private Capital Group LLC now owns 681 shares of the company’s stock worth $25,000 after acquiring an additional 531 shares during the period. Quest Capital Management Inc. ADV purchased a new stake in Qiagen in the third quarter worth $37,000. Huntington National Bank increased its position in Qiagen by 33.3% in the third quarter. Huntington National Bank now owns 1,568 shares of the company’s stock worth $52,000 after buying an additional 392 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Qiagen by 1,244.7% in the second quarter. Tower Research Capital LLC TRC now owns 1,385 shares of the company’s stock worth $56,000 after buying an additional 1,282 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Qiagen by 25.8% in the third quarter. Tower Research Capital LLC TRC now owns 1,742 shares of the company’s stock worth $57,000 after buying an additional 357 shares during the last quarter. Institutional investors and hedge funds own 61.95% of the company’s stock.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Read More: Limitations to arbitrage trading

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.